scholarly journals Research Progress in Targeted Therapy of Hepatocellular Carcinoma

2021 ◽  
Vol 36 (1) ◽  
pp. 57-65
Author(s):  
Chen Qiong ◽  
Yang Xuefeng ◽  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Therapy ◽  
Research Progress

Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma

2020 ◽  
Vol 27 ◽  
Author(s):  
Tao Wang ◽  
Qiting Zhang ◽  
Ning Wang ◽  
Ziqi Liu ◽  
Bin Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Therapy ◽  
Malignant Tumors ◽  
Checkpoint Inhibitors ◽  
Modern Medicine ◽  
Vital Role ◽  
Research Progress ◽  
Molecular Targeting Drug ◽  
Further Development ◽  
Made In

: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, with nearly one million new cases and deaths every year. Owing to the complex pathogenesis, hidden early symptoms, rapidly developing processes and poor prognosis, the morbidity and mortality of HCC are increasing yearly. With the progress being made in modern medicine, the treatment of HCC is no longer limited to traditional methods. Targeted therapy and immunotherapy have emerged to treat advanced and metastatic HCC in recent years. Since Sorafenib is the first molecular targeting drug against angiogenesis, targeted drugs for HCC are continually emerging. Moreover, immunotherapy plays a vital role in clinical trials. In particular, the application of immune checkpoint inhibitors, which have received increasing attention in the field of cancer treatment, is a possible research path. Interestingly, these two therapies generally complement each other at some stages of HCC, bringing new hope for patients with advanced HCC. In this paper, we discuss the research progress of targeted therapy and immunotherapy for HCC in recent years, which will provide a reference for the further development of drugs for HCC.

scholarly journals Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma

BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Winnie Yeo ◽  
Pei-Jer Chen ◽  
Junji Furuse ◽  
Kwang-Hyub Han ◽  
Chiun Hsu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Molecular Targeted Therapy ◽  
Expert Panel

scholarly journals How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma

2016 ◽  
Vol 8 (35) ◽  
pp. 1541 ◽  
Author(s):  
Jean-Luc Raoul ◽  
Xavier Adhoute ◽  
Marine Gilabert ◽  
Julien Edeline
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Therapy

scholarly journals The Expression and Function of Circadian Rhythm Genes in Hepatocellular Carcinoma

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Yanan Jiang ◽  
Xiuyun Shen ◽  
Moyondafoluwa Blessing Fasae ◽  
Fengnan Zhi ◽  
Lu Chai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Circadian Rhythm ◽  
Circadian Rhythms ◽  
Molecular Mechanisms ◽  
Therapeutic Targets ◽  
Pathogenic Mechanism ◽  
Research Progress ◽  
Biological Processes ◽  
And Function ◽  
Novel Therapeutic

Hepatocellular carcinoma (HCC) is among the most common and lethal form of cancer worldwide. However, its diagnosis and treatment are still dissatisfactory, due to limitations in the understanding of its pathogenic mechanism. Therefore, it is important to elucidate the molecular mechanisms and identify novel therapeutic targets for HCC. Circadian rhythm-related genes control a variety of biological processes. These genes play pivotal roles in the initiation and progression of HCC and are potential diagnostic markers and therapeutic targets. This review gives an update on the research progress of circadian rhythms, their effects on the initiation, progression, and prognosis of HCC, in a bid to provide new insights for the research and treatment of HCC.

scholarly journals Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244304
Author(s):  
Hwaseong Ryu ◽  
Jung Hoon Kim ◽  
Seunghyun Lee ◽  
Joon Koo Han
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Therapy ◽  
Treatment Group ◽  
Rat Model ◽  
Therapeutic Response ◽  
Response Monitoring ◽  
Control Group ◽  
Rat Models ◽  
Significant Change ◽  
Operator Reproducibility

Purpose To assess therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma (HCC) using CEUS with focusing on inter-scanner and inter-operator reproducibility. Materials and methods For reproducibility, CEUS was performed using two different US scanners by two operators in sixteen rat models of HCC. Using perfusion analysis software (VueBox ®), eleven parameters were collected, and intra-class correlation coefficient (ICC) was used to analyze reproducibility. Then seventeen rat models of HCC were divided into treatment group (n = 8, 30 mg/kg/day sorafenib for five days) and control group (n = 9). CEUS was performed at baseline and 14 days after first treatment, and changes of perfusion parameters were analyzed. Results In treatment group, CEUS perfusion parameters showed a significant change. The peak enhancement (PE, 2.50 x103±1.68 x103 vs 5.55x102±4.65x102, p = 0.010) and wash-in and wash out AUC (WiWoAUC, 1.07x105±6.48 x104 vs 2.65x104±2.25x104, p = 0.009) had significantly decreased two weeks after treatment. On the contrary, control group did not show a significant change, including PE (1.15 x103±7.53x102 vs 9.43x102± 7.81 x102, p = 0.632) and WiWoAUC (5.09 x104±3.25x104 vs 5.92 x104±3.20x104, p = 0.646). For reproducibility, the various degrees of inter-scanner reproducibility were from poor to good (ICC: <0.01–0.63). However, inter-operator reproducibility of important perfusion parameters, including WiAUC, WoAUC, and WiWoAUC, ranged from fair to excellent (ICC: 0.59–0.93) in a different scanner. Conclusion Our results suggest that CEUS is useful for assessment of the treatment response after targeted therapy and with fair to excellent inter-operator reproducibility.

Sign in / Sign up

Export Citation Format

Share Document